{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:04:48Z","timestamp":1785884688975,"version":"3.56.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T00:00:00Z","timestamp":1666051200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T00:00:00Z","timestamp":1666051200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000276","name":"Department of Health and Social Care","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000276","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Aim<\/jats:title>\n                <jats:p>To inform the oversight of future clinical trials during a pandemic, we summarise the experiences of the Data Monitoring Committee (DMC) for the Randomised Evaluation of COVID therapy trial (RECOVERY), a large-scale randomised adaptive platform clinical trial of treatments for hospitalised patients with COVID-19.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods and findings<\/jats:title>\n                <jats:p>During the first 24\u00a0months of the trial (March 2020 to February 2022), the DMC oversaw accumulating data for 14 treatments in adults (plus 10 in children) involving\u2009&gt;\u200945,000 randomised patients. Five trial aspects key for the DMC in performing its role were: a large committee of members, including some with extensive DMC experience and others who had broad clinical expertise; clear strategic planning, communication, and responsiveness by the trial principal investigators; data collection and analysis systems able to cope with phases of very rapid recruitment and link to electronic health records; an ability to work constructively with regulators (and other DMCs) to address emerging concerns without the need to release unblinded mortality results; and the use of videoconferencing systems that enabled national and international members to meet at short notice and from home during the pandemic when physical meetings were impossible. Challenges included that the first four treatments introduced were effectively \u2018competing\u2019 for patients (increasing pressure to make rapid decisions on each one); balancing the global health imperative to report on findings with the need to maintain confidentiality until the results were sufficiently certain to appropriately inform treatment decisions; and reliably assessing safety, especially for newer agents introduced after the initial wave and in the small numbers of pregnant women and children included. We present a series of case vignettes to illustrate some of the issues and the DMC decision-making related to hydroxychloroquine, dexamethasone, casirivimab\u2009+\u2009imdevimab, and tocilizumab.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>RECOVERY\u2019s streamlined adaptive platform design, linked to hospital-level and population-level health data, enabled the rapid and reliable assessment of multiple treatments for hospitalised patients with COVID-19. The later introduction of factorial assessments increased the trial\u2019s efficiency, without compromising the DMC\u2019s ability to assess safety and efficacy. Requests for the release of unblinded primary outcome data to regulators at points when data were not mature required significant efforts in communication with the regulators by the DMC to avoid inappropriate early trial termination.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13063-022-06824-6","type":"journal-article","created":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T18:05:22Z","timestamp":1666116322000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Experiences of the Data Monitoring Committee for the RECOVERY trial, a large-scale adaptive platform randomised trial of treatments for patients hospitalised with COVID-19"],"prefix":"10.1186","volume":"23","author":[{"given":"Peter A. G.","family":"Sandercock","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Darbyshire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"DeMets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Fowler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Lalloo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Munavvar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Staplin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adilia","family":"Warris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Wittes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7792-9422","authenticated-orcid":false,"given":"Jonathan R.","family":"Emberson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,18]]},"reference":[{"key":"6824_CR1","unstructured":"Herson J. Data and Safety monitoring committees in clinical trials. Boca Raton: Chapman & Hall\/CRC Biostatistics Series, CRC Press;\u00a02009."},{"key":"6824_CR2","doi-asserted-by":"publisher","DOI":"10.1002\/0470854162","volume-title":"Data monitoring committees in clinical trials: a practical perspective","author":"SS Ellenberg","year":"2002","unstructured":"Ellenberg SS, Fleming TR, DeMets DL. Data monitoring committees in clinical trials: a practical perspective. Chichester: Wiley; 2002."},{"key":"6824_CR3","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.jclinepi.2020.07.001","volume":"126","author":"DL DeMets","year":"2020","unstructured":"DeMets DL, Fleming TR. Achieving effective informed oversight by DMCs in COVID clinical trials. J Clin Epidemiol. 2020;126:167\u201371.","journal-title":"J Clin Epidemiol"},{"issue":"8","key":"6824_CR4","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1056\/NEJMoa2021436","volume":"384","author":"RECOVERY Collaborative Group","year":"2021","unstructured":"RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with COVID-19. New Engl J Med. 2021;384(8):693\u2013704.","journal-title":"New Engl J Med"},{"issue":"21","key":"6824_CR5","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1056\/NEJMoa2022926","volume":"383","author":"RECOVERY Collaborative Group","year":"2020","unstructured":"RECOVERY Collaborative Group. Effect of hydroxychloroquine in hospitalized patients with COVID-19. New Engl J Med. 2020;383(21):2030\u201340.","journal-title":"New Engl J Med"},{"issue":"10259","key":"6824_CR6","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/S0140-6736(20)32013-4","volume":"396","author":"RECOVERY Collaborative Group","year":"2020","unstructured":"RECOVERY Collaborative Group. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2020;396(10259):1345\u201352.","journal-title":"Lancet"},{"issue":"10274","key":"6824_CR7","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/S0140-6736(21)00149-5","volume":"397","author":"RECOVERY Collaborative Group","year":"2021","unstructured":"RECOVERY Collaborative Group. Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397(10274):605\u201312.","journal-title":"Lancet"},{"issue":"12","key":"6824_CR8","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1016\/S2213-2600(21)00435-5","volume":"9","author":"RECOVERY Collaborative Group","year":"2021","unstructured":"RECOVERY Collaborative Group. Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet Resp Med. 2021;9(12):1419\u201326.","journal-title":"Lancet Resp Med"},{"issue":"10285","key":"6824_CR9","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/S0140-6736(21)00676-0","volume":"397","author":"RECOVERY Collaborative Group","year":"2021","unstructured":"RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397(10285):1637\u201345.","journal-title":"Lancet"},{"issue":"10289","key":"6824_CR10","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1016\/S0140-6736(21)00897-7","volume":"397","author":"RECOVERY Collaborative Group","year":"2021","unstructured":"RECOVERY Collaborative Group. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet. 2021;397(10289):2049\u201359.","journal-title":"Lancet"},{"issue":"10320","key":"6824_CR11","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S0140-6736(21)01825-0","volume":"399","author":"RECOVERY Collaborative Group","year":"2022","unstructured":"RECOVERY Collaborative Group. Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2022;399(10320):143\u201351.","journal-title":"Lancet"},{"issue":"10325","key":"6824_CR12","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0140-6736(22)00163-5","volume":"399","author":"RECOVERY Collaborative Group","year":"2022","unstructured":"RECOVERY Collaborative Group. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2022;399(10325):665\u201376.","journal-title":"Lancet"},{"issue":"10349","key":"6824_CR13","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/S0140-6736(22)01109-6","volume":"400","author":"RECOVERY Collaborative Group","year":"2022","unstructured":"RECOVERY Collaborative Group. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. Lancet. 2022;400(10349):359\u201368.","journal-title":"Lancet"},{"issue":"7","key":"6824_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta9070","volume":"9","author":"AM Grant","year":"2005","unstructured":"Grant AM, Altman DG, Babiker AB, Campbell MK, Clemens FJ, Darbyshire JH, et al. Issues in data monitoring and interim analysis of trials. Health Technol Assess. 2005;9(7):1\u2013238 (iii-iv).","journal-title":"Health Technol Assess."},{"issue":"5","key":"6824_CR15","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1177\/1740774514534347","volume":"11","author":"J Pogue","year":"2014","unstructured":"Pogue J, Sackett DL. Clinician-trialist rounds: 23. When an RCT\u2019s Data Center Report drowns vital information in seas of data: where\u2019s Waldo? Clinical Trials. 2014;11(5):601\u20134.","journal-title":"Clinical Trials."},{"issue":"1","key":"6824_CR16","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1177\/17407745211051279","volume":"19","author":"DL DeMets","year":"2022","unstructured":"DeMets DL, Wittes J. Data monitoring committee interim reports: we must get there soon! Clin Trials. 2022;19(1):107\u201311.","journal-title":"Clin Trials"},{"key":"6824_CR17","unstructured":"RECOVERY Trial Steering Committee. RECOVERY protocol v1.0 (2020\u201303\u201318) [Available from: https:\/\/www.recoverytrial.net\/files\/protocol-archive\/recovery-protocol-v1-0-2020-03-18-final.pdf."},{"issue":"526","key":"6824_CR18","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1259\/0007-1285-44-526-793","volume":"44","author":"JL Haybittle","year":"1971","unstructured":"Haybittle JL. Repeated assessment of results in clinical trials of cancer treatment. Br J Radiol. 1971;44(526):793\u20137.","journal-title":"Br J Radiol"},{"issue":"6","key":"6824_CR19","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/bjc.1976.220","volume":"34","author":"R Peto","year":"1976","unstructured":"Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer. 1976;34(6):585\u2013612.","journal-title":"Br J Cancer."},{"key":"6824_CR20","doi-asserted-by":"crossref","unstructured":"Ellenberg SS, Fleming TR, DeMets D. Regulatory considerations for the operation of data monitoring committees. In: Data monitoring committees in clinical trials: a practical perspective. Chichester: Wiley;\u00a02002.","DOI":"10.1002\/0470854162"},{"issue":"9940","key":"6824_CR21","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/S0140-6736(14)61122-3","volume":"384","author":"MK Parmar","year":"2014","unstructured":"Parmar MK, Carpenter J, Sydes MR. More multiarm randomised trials of superiority are needed. Lancet. 2014;384(9940):283\u20134.","journal-title":"Lancet"},{"issue":"9194","key":"6824_CR22","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1016\/S0140-6736(99)03464-9","volume":"354","author":"DL DeMets","year":"1999","unstructured":"DeMets DL, Pocock SJ, Julian DG. The agonising negative trend in monitoring of clinical trials. Lancet. 1999;354(9194):1983\u20138.","journal-title":"Lancet"},{"issue":"10240","key":"6824_CR23","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1016\/S0140-6736(20)31324-6","volume":"395","author":"MR Mehra","year":"2020","unstructured":"Mehra MR, Ruschitzka F, Patel AN. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet. 2020;395(10240):1820 (Retraction of https:\/\/doi.org\/10.1016\/S0140-6736(20)31180-6, 2020).","journal-title":"Lancet."},{"key":"6824_CR24","unstructured":"Oxford University. PRESS RELEASE: no clinical benefit from use of hydroxychloroquine in hospitalised patients with COVID-19. Available from:\u00a0https:\/\/www.recoverytrial.net\/files\/hcq-recovery-statement-050620-final-002.pdf."},{"key":"6824_CR25","unstructured":"BBC. Coronavirus: dexamethasone proves first life-saving drug 2020 [Available from: https:\/\/www.bbc.co.uk\/news\/health-53061281."},{"key":"6824_CR26","unstructured":"Oxford University. PRESS RELEASE: low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19 [Available from: https:\/\/www.recoverytrial.net\/files\/recovery_dexamethasone_statement_160620_v2final.pdf."},{"issue":"15","key":"6824_CR27","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1001\/jama.2013.280383","volume":"310","author":"PW Armstrong","year":"2013","unstructured":"Armstrong PW, Califf RM. Data and safety monitoring boards academic credit where credit is due? Jama-J Am Med Assoc. 2013;310(15):1563\u20134.","journal-title":"Jama-J Am Med Assoc"},{"issue":"7","key":"6824_CR28","doi-asserted-by":"publisher","first-page":"e0201037","DOI":"10.1371\/journal.pone.0201037","volume":"13","author":"C Snowdon","year":"2018","unstructured":"Snowdon C, Brocklehurst P, Tasker RC, Ward Platt M, Elbourne D. \u201cYou have to keep your nerve on a DMC.\u201d Challenges for data monitoring committees in neonatal intensive care trials: Qualitative accounts from the BRACELET Study. PloS one. 2018;13(7):e0201037.","journal-title":"PloS one."}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06824-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-022-06824-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06824-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T18:05:35Z","timestamp":1666116335000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-022-06824-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,18]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["6824"],"URL":"https:\/\/doi.org\/10.1186\/s13063-022-06824-6","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,18]]},"assertion":[{"value":"30 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval for the trial was provided by the Cambridge East Research Ethics Committee (ref: 20\/EE\/0101). Written informed consent was obtained from all the patients or from a legal representative if they were unable to provide consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have seen and approved the final version and agree to its submission for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"PS is the Chair of the DMC for the ORION-4 study sponsored by the Nuffield Department of Population Health at the University of Oxford, for which he receives fees and expenses. DD is a consultant to the National Institutes of Health, the Food and Drug Administration, and the pharmaceutical and medical device industry on the design, monitoring, and analysis of clinical trials. He receives compensation for serving on several industry-sponsored data and safety monitoring committees including Astra Zeneca, Amgen, Actelion, Bristol Meyers Squib, DalCor, GSK, Merck, Sanofi, Boston Scientific, Medtronic, Mesoblast, Intercept, Duke Clinical Research Institute, and Population Health Research Institute of Hamilton. He holds no stock in any pharmaceutical or device company. JD, RF, DL, MM, NS, AW, JW,\u00a0and JRE declare that they have no competing interests. None of the authors received any payment to serve on the RECOVERY DMC.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"881"}}